Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-06-30 View official record Methodology

Covered recipient · General Payments record

ENRICO M NOVELLI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1033243639
CMS profile
876433
Location
PITTSBURGH, PA

General Payments · PY2019–2025

$175,959.41

  • Reported across 41 records
  • CMS publication 2026-06-30

Latest program year · PY2025

$61,821.63

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2025 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $47,920.00 4
Travel and Lodging $13,439.17 6
Food and Beverage $462.46 3

By paying entity

PY2025 · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Health Care AG $59,709.63 11
NOVARTIS PHARMACEUTICALS CORPORATION $2,070.00 1
VERTEX PHARMACEUTICALS INCORPORATED $42.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $106.32 1
PY2022 $112.13 1
PY2023 $34,293.67 9
PY2024 $79,625.66 17
PY2025 $61,821.63 13

Payment records · PY2025 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2025 2019202220232024 Record-level detail is published for PY2025; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Novartis Pharmaceuticals Corporation $2,070.00 09/18/2025 Consulting Fee Undisputed 06/30/2026 1200751284 CMS
Novo Nordisk Health Care AG $4,912.50 02/01/2025 Consulting Fee Undisputed 06/30/2026 1186253710 CMS
Novo Nordisk Health Care AG $160.00 06/06/2025 Food and Beverage Undisputed 06/30/2026 1186253548 CMS
Novo Nordisk Health Care AG $14,246.25 06/06/2025 Consulting Fee Undisputed 06/30/2026 1186253648 CMS
Novo Nordisk Health Care AG $507.57 06/06/2025 Travel and Lodging Undisputed 06/30/2026 1186253794 CMS
Novo Nordisk Health Care AG $5,081.60 06/06/2025 Travel and Lodging Undisputed 06/30/2026 1186253820 CMS
Novo Nordisk Health Care AG $515.00 06/06/2025 Travel and Lodging Undisputed 06/30/2026 1186253882 CMS
Novo Nordisk Health Care AG $498.00 09/01/2025 Travel and Lodging Undisputed 06/30/2026 1186253602 CMS
Novo Nordisk Health Care AG $260.46 09/01/2025 Food and Beverage Undisputed 06/30/2026 1186253618 CMS
Novo Nordisk Health Care AG $6,391.12 09/01/2025 Travel and Lodging Undisputed 06/30/2026 1186253764 CMS
Novo Nordisk Health Care AG $26,691.25 09/01/2025 Consulting Fee Undisputed 06/30/2026 1186253814 CMS
Novo Nordisk Health Care AG $445.88 09/01/2025 Travel and Lodging Undisputed 06/30/2026 1186253850 CMS
VERTEX PHARMACEUTICALS INCORPORATED $42.00 12/07/2025 Food and Beverage Undisputed 06/30/2026 1213914068 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.